ImmunoGen (NASDAQ:IMGN)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a research note issued to investors on Thursday. They currently have a $12.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 36.99% from the stock’s current price.
IMGN has been the topic of a number of other research reports. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Tuesday, October 31st. Jefferies Group reiterated a “buy” rating and set a $9.00 price objective on shares of ImmunoGen in a research report on Thursday, October 12th. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 price objective on shares of ImmunoGen in a research report on Friday, November 3rd. HC Wainwright assumed coverage on ImmunoGen in a research report on Wednesday, January 31st. They set a “buy” rating on the stock. Finally, BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. ImmunoGen currently has an average rating of “Buy” and a consensus price target of $7.83.
Shares of ImmunoGen (IMGN) traded down $0.25 during trading on Thursday, reaching $8.76. The company had a trading volume of 4,243,525 shares, compared to its average volume of 2,980,000. ImmunoGen has a 52-week low of $2.30 and a 52-week high of $10.04. The stock has a market capitalization of $1,360.00, a P/E ratio of -6.74 and a beta of 2.50. The company has a debt-to-equity ratio of -0.03, a quick ratio of 2.78 and a current ratio of 2.81.
ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/08/royal-bank-of-canada-reaffirms-outperform-rating-for-immunogen-imgn.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.